Acute Ischemic Stroke Treatment and Diagnosis Market

Acute Ischemic Stroke Treatment and Diagnosis Market by Treatment (Devices [Thrombectomy Devices, Embolic Protection Devices, Clot Retrieval Devices, and Stents] and Drugs [Thrombolytic Drugs, Anticoagulants, Antiplatelet Agents, and Neuroprotective Agents]), Diagnosis Type (Magnetic Resonance Imaging (MRI), Computed Tomography, Cerebral Angiography, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing incidence of stroke, and rising prevalence of risk factors leading to stroke such as hypertension, diabetes, and obesity.

The acute ischemic stroke treatment and diagnosis market was valued at USD 4,686.39 million in 2024, growing at a CAGR of 4.85% during the forecast period from 2025 to 2032 to reach USD 6,811.05 million by 2032. The increasing incidence of strokes, driven by an aging population and lifestyle changes, has heightened the demand for effective treatment options. Concurrently, the rising prevalence of risk factors such as hypertension, diabetes, and obesity has led to a greater awareness of stroke prevention and management, prompting healthcare providers to seek advanced therapeutics. Additionally, ongoing product development activities, including innovative drug formulations and delivery methods, are enhancing the efficacy and safety profiles of acute ischemic stroke treatment and diagnosis. These advancements not only improve patient outcomes but also attract investments and encourage research initiatives, further expanding the market. Together, these factors are expected to boost consumer engagement and drive the growth of the acute ischemic stroke treatment and diagnosis market during the forecast period from 2025 to 2032.

Acute Ischemic Stroke Treatment and Diagnosis Market Dynamics:

According to the World Stroke Organization (2022), globally, there are over 12.2 million new stroke cases of stroke every year. Globally, one in four people over age 25 will have a stroke in their lifetime. Additionally, as per the same source, there were over 7.6 million new ischemic strokes each year, and globally, over 62% of all incident strokes were ischemic strokes. Furthermore, each year, over 11% of all ischemic strokes occur in people 15-49 years of age, over 58% of all ischemic strokes occur in people under 70 years of age, 45% of all ischemic strokes occur in men, and 55% of all ischemic strokes occur in women.

Increased stroke cases heighten the urgency for timely diagnosis, leading to a surge in the adoption of imaging techniques such as CT scans and MRIs, which are crucial for identifying acute ischemic strokes. Furthermore, devices such as mechanical thrombectomy systems, which are designed to remove blood clots from blocked arteries, have become essential tools in emergency care settings. The growing stroke population increases demand for these devices, encouraging manufacturers to innovate and enhance their offerings to improve efficacy and safety thereby boosting the overall market of acute ischemic stroke.

Additionally, the growing product development activities across the globe are further boosting the overall market of acute ischemic stroke. For instance, in February 2024, CERENOVUS Inc., part of Johnson & Johnson MedTech launched the next-generation catheter CEREGLIDE™ 71 for revascularization of patients with acute ischemic stroke.

Thus, the factors mentioned above are expected to boost the overall market of acute ischemic stroke across the globe during the forecast period from 2025 to 2032.

However, the risk of complications such as arterial rupture, bleeding, or re-occlusion of the treated vessel after thrombectomy and stringent regulatory concerns for acute ischemic stroke products may result in slight obstacles to the growth of the acute ischemic stroke market.

Acute Ischemic Stroke Treatment and Diagnosis Market Segment Analysis:

Acute Ischemic Stroke Treatment and Diagnosis Market by Treatment (Devices [Thrombectomy Devices, Embolic Protection Devices, Clot Retrieval Devices, and Stents] and Drugs [Thrombolytic Drugs, Anticoagulants, Antiplatelet Agents, and Neuroprotective Agents]), Diagnosis Type (Magnetic Resonance Imaging (MRI), Computed Tomography, Cerebral Angiography, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) 

In the treatment segment of the acute ischemic stroke treatment and diagnosis market, the thrombectomy device is estimated to have a significant revenue share in the acute ischemic stroke treatment and diagnosis market in 2024. Thrombectomy devices are significantly boosting the overall market of acute ischemic stroke (AIS) by offering a revolutionary treatment option for patients who cannot benefit from traditional thrombolytic therapies like tissue plasminogen activator (tPA). These devices, such as stent retrievers and aspiration catheters, allow for the mechanical removal of blood clots from blocked arteries, restoring blood flow to the brain. One of the key drivers of their market growth is the expanding eligibility window; advancements in technology have extended the effective treatment window from 6 hours to up to 24 hours after stroke onset, enabling more patients to receive timely intervention. For instance, in May 2024, Rapid Medical™, a leading developer of advanced neurovascular devices, announced the first successful robotic thrombectomy in Medellín, Colombia. Two patients were treated with the Robotic TIGERTRIEVER™, the first endovascular thrombectomy device that adapts autonomously to the patient’s anatomy.

Additionally, thrombectomy procedures are associated with better patient outcomes, such as reduced disability and lower rates of post-stroke complications, which lowers the burden on healthcare systems in the long run and encourages adoption. Furthermore, favorable clinical trial results, such as the DAWN and DEFUSE 3 studies, have validated thrombectomy as a gold standard treatment for large vessel occlusion (LVO) strokes, spurring further product development and regulatory approvals. As these devices demonstrate higher efficacy and safety compared to conventional methods, they are becoming essential in the treatment landscape, thereby boosting the market for thrombectomy devices and hence boosting the overall market of acute ischemic stroke across the globe.

North America is expected to dominate the overall acute ischemic stroke treatment and diagnosis market:

North America is expected to account for the highest proportion of the acute ischemic stroke treatment and diagnosis market in 2024, out of all regions. The increasing incidence of stroke due to the growing aging population and lifestyle-related risk factors such as hypertension, obesity, diabetes, and smoking are driving the overall market of acute ischemic stroke. Advancements in healthcare infrastructure, such as the expansion of specialized stroke centers, have improved access to emergency stroke care, further propelling market growth. The adoption of advanced treatment devices, including mechanical thrombectomy and neurovascular stents, supported by favorable clinical guidelines, is enhancing patient outcomes and boosting demand. Additionally, growing investments in research and product development, along with supportive reimbursement policies for stroke treatment, are accelerating the market's expansion across the region.

According to the recent data and stats provided by the Centre for Disease Control and Prevention (2024), the number of adults who ever had a stroke was 7.8 million in the United States. Thus, the rising incidence of stroke, particularly acute ischemic stroke, is significantly driving the acute ischemic stroke treatment and diagnosis market by increasing the demand for rapid and effective treatment options. As more people experience strokes due to aging populations there is a growing need for advanced therapeutic solutions such as thrombolytic drugs and thrombectomy devices across the region.

Furthermore, obesity is a major risk factor for acute ischemic stroke (AIS) and is significantly driving the growth of the AIS treatment market. According to the recent data provided by the Centre for Disease Control and Prevention (2024), the prevalence of severe obesity among U.S. adults was 9.2%. Approximately, more than 100 million adults had obesity, and more than 22 million adults had severe obesity. Thus, obesity contributes to the development of other stroke-related conditions, such as hypertension, diabetes, and hyperlipidemia, all of which increase the likelihood of stroke. As global obesity rates rise, the incidence of AIS also climbs, resulting in greater demand for both preventive care and advanced treatment solutions.

Furthermore, the ongoing strategic activities among the key market players are further boosting the overall market of acute ischemic stroke across the region. For instance, in December 2023, Perfuze® announced the FDA clearances for novel neurovascular aspiration and access catheters Millipede 070 Aspiration Catheter and the 2nd generation of the Millipede 088 Access Catheter for acute ischemic stroke treatment and diagnosis.

Thus, the above-mentioned factors are expected to escalate the market of acute ischemic stroke in the region.

Acute Ischemic Stroke Treatment and Diagnosis Market Key Players:

Some of the key market players operating in the acute ischemic stroke treatment and diagnosis market include Medtronic PLC, Abbott, Stryker, Johnson & Johnson Services, Inc., Terumo Corporation, Toro Neurovascular, Ceretrieve, Perfuze Ltd., CERENOVUS Inc., Rapid Medical, Boston Scientific Corporation, MicroVention, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Sanofi, Pfizer, Inc., AstraZeneca, Penumbra, Inc., Inari Medical, Inc., InspireMD, Inc., and others.

Recent Developmental Activities in the Acute Ischemic Stroke Treatment and Diagnosis Market:

• In May 2024, Ceretrieve announced successful results from its multicenter, single-arm study evaluating its advanced aspiration catheter. Conducted at two centers, the study involved 20 acute ischemic stroke (AIS) patients with intracranial large vessel occlusion (LVO) eligible for thrombectomy within 24 hours. The study assessed the device’s safety and initial performance.
• In September 2023, Toro Neurovascular announced the successful treatment of the first patient of acute ischemic stroke using its Toro 88 SuperBore Aspiration Catheter in a first-in-man clinical study.

Key Takeaways From the Acute Ischemic Stroke Treatment and Diagnosis Market Report Study

• Market size analysis for current acute ischemic stroke treatment and diagnosis size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the acute ischemic stroke treatment and diagnosis market.
• Various opportunities available for the other competitors in the acute ischemic stroke treatment and diagnosis market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current acute ischemic stroke treatment and diagnosis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for acute ischemic stroke treatment and diagnosis market growth in the coming future?

Target Audience Who Can be Benefited From This Acute Ischemic Stroke Treatment and Diagnosis Market Report Study

• Acute ischemic stroke product providers
• Research organizations and consulting companies 
• Acute ischemic stroke -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in acute ischemic stroke 
• Various end-users who want to know more about the acute ischemic stroke treatment and diagnosis market and the latest technological developments in the acute ischemic stroke treatment and diagnosis market.  

Frequently Asked Questions for the Acute Ischemic Stroke Treatment and Diagnosis Market:

1. What is an acute ischemic stroke?

• Acute ischemic stroke occurs when a blood clot or obstruction blocks blood flow to the brain, leading to cell damage or death. It requires immediate medical intervention to restore circulation and minimize brain injury.

2. What is the market for acute ischemic stroke treatment and diagnosis?

• The acute ischemic stroke treatment and diagnosis market was valued at USD 4,686.39 million in 2024, growing at a CAGR of 4.85% during the forecast period from 2025 to 2032 to reach USD 6,811.05 million by 2032. 

3. What are the drivers for the acute ischemic stroke treatment and diagnosis market?

• The increasing incidence of strokes, driven by an aging population and lifestyle changes, has heightened the demand for effective treatment options. Concurrently, the rising prevalence of risk factors such as hypertension, diabetes, and obesity has led to a greater awareness of stroke prevention and management, prompting healthcare providers to seek advanced therapeutics. Additionally, ongoing product development activities, including innovative drug formulations and delivery methods, are enhancing the efficacy and safety profiles of acute ischemic stroke treatment and diagnosis. These advancements not only improve patient outcomes but also attract investments and encourage research initiatives, further expanding the market. Together, these factors are expected to boost consumer engagement and drive the growth of the acute ischemic stroke treatment and diagnosis market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the acute ischemic stroke treatment and diagnosis market?

• Some of the key market players operating in acute ischemic stroke are Medtronic PLC, Abbott, Stryker, Johnson & Johnson Services, Inc., Terumo Corporation, Toro Neurovascular, Ceretrieve, Perfuze Ltd., CERENOVUS Inc., Rapid Medical, Boston Scientific Corporation, MicroVention, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Sanofi, Pfizer, Inc., AstraZeneca, Penumbra, Inc., Inari Medical, Inc., InspireMD, Inc., and others.

5. Which region has the highest share in the global acute ischemic stroke treatment and diagnosis market?

• North America is expected to account for the highest proportion of the acute ischemic stroke treatment and diagnosis market in 2024, out of all regions. The increasing incidence of stroke due to aging populations and lifestyle-related risk factors such as hypertension, obesity, diabetes, and smoking is driving the overall market of acute ischemic stroke. Advancements in healthcare infrastructure, such as the expansion of specialized stroke centers, have improved access to emergency stroke care, further propelling market growth. Additionally, growing investments in research and product development, along with supportive reimbursement policies for stroke treatment, are accelerating the market's expansion across the region.